A patient-oriented approach to the use of rHuEpo for preventing allogeneic blood transfusion in individuals facing elective surgery. Mildly to moderate anemic individuals, patients with small body weight and low predicted blood volume (primarily females), and those with an anticipated blood loss of 1 to 2 L are most likely to benefit from rHuEpo treatment. See also Table 3 for details.